Tags : Ferring

Ferring and Blackstone Collaborate to Establish Joint Venture Focusing on

Shots: Ferring launches a new company FerGene focusing the global development and commercialization of Nadofaragene firadenovec in the US for the patients with Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer Blackstone to invest $400M and its expertise to accelerate the future development and commercialization of Nadofaragene firadenovec while Ferring will invest up to $170M […]Read More

Ferring Signs an Exclusive License Agreement with Invo for its

Shots: Ferring to receive the US commercialization rights for INVOcell Technology and Invo will take care of its manufacturing and supplying activities for Ferring Invo has rights to establish INVO clinics for exclusive commercialization of INVOcell outside the US. The agreement is expected to close in Jan, 2019 INVOcell is a novel technology with small […]Read More

Ferring Signs a Research Colllaboration with Evotec to Develop Novel

Shots: Evotec to provide Ferring its discovery and development platform to develop novel therapies in fertility and gynecology and will also receive upfronts and milestone payments The multi-target and multi-year collaboration is providing PDC & IND candidates for gynaecological conditions The collaboration focusses on developing and providing therapies for families and with a motive to […]Read More